Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline

Catherine Van Poznak, Mark R. Somerfield, Robert C. Bast, Massimo Cristofanilli, Matthew Philip Goetz, Ana M. Gonzalez-Angulo, David G. Hicks, Elizabeth G. Hill, Minetta C Liu, Wanda Lucas, Ingrid A. Mayer, Robert G. Mennel, William F. Symmans, Daniel F. Hayes, Lyndsay N. Harris

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Purpose: To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods: A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective-retrospective studies that evaluated the clinical utility of biomarkers. Recommendations: In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.

Original languageEnglish (US)
Pages (from-to)2695-2704
Number of pages10
JournalJournal of Clinical Oncology
Volume33
Issue number24
DOIs
StatePublished - Aug 20 2015

Fingerprint

Practice Guidelines
Biomarkers
Breast Neoplasms
Progesterone Receptors
Tumor Biomarkers
Neoplasm Metastasis
Estrogen Receptors
Neoplasms
Randomized Controlled Trials
Retrospective Studies
Prospective Studies
Patient Care Planning
Therapeutics
Antigens
Carcinoembryonic Antigen
Observational Studies
Meta-Analysis
Patient Care
Hormones
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer : American Society of Clinical Oncology clinical practice guideline. / Van Poznak, Catherine; Somerfield, Mark R.; Bast, Robert C.; Cristofanilli, Massimo; Goetz, Matthew Philip; Gonzalez-Angulo, Ana M.; Hicks, David G.; Hill, Elizabeth G.; Liu, Minetta C; Lucas, Wanda; Mayer, Ingrid A.; Mennel, Robert G.; Symmans, William F.; Hayes, Daniel F.; Harris, Lyndsay N.

In: Journal of Clinical Oncology, Vol. 33, No. 24, 20.08.2015, p. 2695-2704.

Research output: Contribution to journalArticle

Van Poznak, C, Somerfield, MR, Bast, RC, Cristofanilli, M, Goetz, MP, Gonzalez-Angulo, AM, Hicks, DG, Hill, EG, Liu, MC, Lucas, W, Mayer, IA, Mennel, RG, Symmans, WF, Hayes, DF & Harris, LN 2015, 'Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline', Journal of Clinical Oncology, vol. 33, no. 24, pp. 2695-2704. https://doi.org/10.1200/JCO.2015.61.1459
Van Poznak, Catherine ; Somerfield, Mark R. ; Bast, Robert C. ; Cristofanilli, Massimo ; Goetz, Matthew Philip ; Gonzalez-Angulo, Ana M. ; Hicks, David G. ; Hill, Elizabeth G. ; Liu, Minetta C ; Lucas, Wanda ; Mayer, Ingrid A. ; Mennel, Robert G. ; Symmans, William F. ; Hayes, Daniel F. ; Harris, Lyndsay N. / Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer : American Society of Clinical Oncology clinical practice guideline. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 24. pp. 2695-2704.
@article{1e945fbe11f14261a064042670e94930,
title = "Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline",
abstract = "Purpose: To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods: A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective-retrospective studies that evaluated the clinical utility of biomarkers. Recommendations: In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.",
author = "{Van Poznak}, Catherine and Somerfield, {Mark R.} and Bast, {Robert C.} and Massimo Cristofanilli and Goetz, {Matthew Philip} and Gonzalez-Angulo, {Ana M.} and Hicks, {David G.} and Hill, {Elizabeth G.} and Liu, {Minetta C} and Wanda Lucas and Mayer, {Ingrid A.} and Mennel, {Robert G.} and Symmans, {William F.} and Hayes, {Daniel F.} and Harris, {Lyndsay N.}",
year = "2015",
month = "8",
day = "20",
doi = "10.1200/JCO.2015.61.1459",
language = "English (US)",
volume = "33",
pages = "2695--2704",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer

T2 - American Society of Clinical Oncology clinical practice guideline

AU - Van Poznak, Catherine

AU - Somerfield, Mark R.

AU - Bast, Robert C.

AU - Cristofanilli, Massimo

AU - Goetz, Matthew Philip

AU - Gonzalez-Angulo, Ana M.

AU - Hicks, David G.

AU - Hill, Elizabeth G.

AU - Liu, Minetta C

AU - Lucas, Wanda

AU - Mayer, Ingrid A.

AU - Mennel, Robert G.

AU - Symmans, William F.

AU - Hayes, Daniel F.

AU - Harris, Lyndsay N.

PY - 2015/8/20

Y1 - 2015/8/20

N2 - Purpose: To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods: A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective-retrospective studies that evaluated the clinical utility of biomarkers. Recommendations: In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.

AB - Purpose: To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods: A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective-retrospective studies that evaluated the clinical utility of biomarkers. Recommendations: In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.

UR - http://www.scopus.com/inward/record.url?scp=84940485164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940485164&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.61.1459

DO - 10.1200/JCO.2015.61.1459

M3 - Article

C2 - 26195705

AN - SCOPUS:84940485164

VL - 33

SP - 2695

EP - 2704

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -